U.S. Patent & Trademark Office (USPTO) Issues Patent To Elorac, Inc. for Treating Chronic Inflammatory Disorders

VERNON HILLS, Ill.--(BUSINESS WIRE)-- Elorac, Inc., a privately held, specialty pharmaceutical company engaged in the development of novel products for dermatology, allergy and oncology, announced that the USPTO has issued to Elorac U.S. Patent No. 9,545,419 entitled “Method and Compositions for Treating Chronic Inflammatory Disorders.”

This patent provides for an immune-modulating composition for treating chronic inflammatory disorders such as psoriasis, rheumatoid arthritis, Crohn’s Disease and uveitis. The composition comprises a complex which inhibits the actions of proinflammatory cytokines and their transduction pathways, including tumor necrosis factor alpha (TNF-α), the Janus kinases and phosphodiesterase 4. Clinical studies in plaque psoriasis and psoriatic arthritis demonstrated impressive efficacy and safety, as well as substantial reductions in serum TNF-α and interleukins.

“We are very pleased to have obtained the patent on the treatment of chronic inflammatory disorders,” said Jeffrey Bernstein, Ph.D., President & Chief Executive Officer. “We believe our product has many advantages over current agents including a very favorable safety profile, significantly reduced patient costs and exceptional efficacy. Our product has the potential to be used as either monotherapy or adjunctive treatment for patients already receiving a biological agent.”

About Elorac, Inc.

Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. Elorac has a robust pipeline of products in development, including naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration, and cidoxepin, a superpotent histamine antagonist, for chronic urticaria and allergic rhinitis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170119006081/en/

Elorac, Inc.
Barry Hollingsworth, Chief Financial Officer
847-362-8200 ext. 230 Direct
[email protected]

Source: Elorac, Inc.

You May Also Be Interested In

• Esaote Group: Shareholders' Meeting approves financial statements as of 31 December 2023
• Omdia research handheld gaming devices will reach 29.3 million in 2028
• Virtu Announces First Quarter 2024 Results